{{Drugbox
| Watchedfields = changed
| verifiedrevid = 433533861
| IUPAC_name = 1-pentyl-3-(8-bromo-1-naphthoyl)indole
| image = JWH-424_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number =  
| ATC_prefix =  
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID      = 28645324

<!--Chemical data-->
| C=24 | H=22 | Br=1 | N=1 | O=1 
| molecular_weight = 420.341 g/mol
| smiles = c4cccc1c4n(CCCCC)cc1C(=O)c(c2c3Br)cccc2ccc3
| StdInChI          = 1S/C24H22BrNO/c1-2-3-6-15-26-16-20(18-11-4-5-14-22(18)26)24(27)19-12-7-9-17-10-8-13-21(25)23(17)19/h4-5,7-14,16H,2-3,6,15H2,1H3
| StdInChIKey       = QXZYVJRMQVOOEQ-UHFFFAOYSA-N

}}

'''JWH-424''' is a drug from the [[naphthoylindole]] family, which acts as a [[cannabinoid]] agonist at both the [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] [[Receptor (biochemistry)|receptors]], but with moderate selectivity for CB<sub>2</sub>, having a [[Dissociation constant#Protein-ligand binding|K<sub>i</sub>]] of 5.44nM at CB<sub>2</sub> vs 20.9nM at CB<sub>1</sub>. The heavier 8-[[Iodine|iodo]] analogue is even more CB<sub>2</sub> selective, with its 2-methyl derivative having 40x selectivity for CB<sub>2</sub>. However the 1-propyl homologues in this series showed much lower affinity at both receptors, reflecting a generally reduced affinity for the 8-substituted naphthoylindoles overall.<ref>Valerie Smith, John Huffman, Jenny Wiley and Billy Martin. EFFECTS OF HALOGEN SUBSTITUENTS UPON CB1 AND CB2 RECEPTOR AFFINITIES IN THE SERIES OF N-ALKYL-3-(8-HALO-1-NAPTHOYL)INDOLES. (2007) 17th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, Page 72.</ref><ref>John W. Huffman, ''et al.'' STRUCTURE-ACTIVITY RELATIONSHIPS AT THE CB1 AND CB2 RECEPTORS FOR 1-ALKYL-3-(1-NAPHTHOYL-4 AND 8-HALOGEN SUBSTITUTED) INDOLES (2009) 19th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, Page 2.</ref>

==See also==
* [[JWH-018]]
* [[JWH-398]]

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Naphthoylindoles]]
[[Category:JWH cannabinoids]]
[[Category:Bromoarenes]]
[[Category:Designer drugs]]


{{cannabinoid-stub}}